DATELINE: WORCESTER, MA…
Dr. Mitchell Sanders, the CEO and Founder of ECI Biotech of Worcester, MA, a premier developer of low cost and rapid diagnostics trademarked as ExpressDetect, was recently a presenter at the 2010 Institute of Biological Engineering (IBE) Annual Conference.
Addressing the BioBusiness Nexus: BioShowcase portion of the conference, Dr. Sanders presented an overview of ECI’s approach to the challenge of translating its technologies into actual products and applications, emphasizing the connection between lab based research and real life applications.
The ExpressDetect sensors that ECI Biotech has developed are low cost, rapid, safe, and simple enough for incorporation into a variety of products that can provide rapid infection diagnostics for use in professional as well as consumer OTC markets. ECI’s target markets for its products include: feminine care, wound care, oral care, and hospital infection control.
Advancing the concept of biology based engineering, ECI’s technologies relate to the detection of microbial pathogens and are of particular value for diagnostic sensors. ECI’s emergent 2011 product line will include diagnostic products targeted at prognosing chronic and acute wound infections which will improve chronic wound care and alleviate patient suffering.”
The Institute of Biological Engineering (IBE) is a professional organization that encourages inquiry and interest in biological engineering. IBE supports the community of scientists and engineers that are addressing global challenges in the environment, resources, energy, health, and sustainability through biological systems analysis and design.
IBE enhances and promotes biological engineering in the broadest manner through research, education, and professional development. The emerging discipline of biological engineering interfaces biological sciences, engineering sciences, mathematics and computational sciences as it applies biological systems to enhance the quality and diversity of life.
Founded in 1998, ECI Biotech is a premier developer of low cost and rapid diagnostics trademarked as ExpressDetect. ECI’s first diagnostic products going to launch in 2011 are targeted at prognosing chronic and acute wound infections. With 18 patents pending and six patents issued, ECI currently has several corporate partnerships with industry leaders in both consumer and professional healthcare.
ECI’s target markets for its products include: wound care, women’s health, oral care, and baby care. ECI Biotech’s product pipeline includes a diagnostic sensor for urinary tract infections, as well as advanced wound care systems that provide early warning of emergent infections and promote healing.
ECI Biotech’s headquarters are located at 85 Prescott Street, in Worcester, Massachusetts. For additional information please contact Dr. Mitchell Sanders at firstname.lastname@example.org, call 508-752-2209, or visit www.ecibiotech.com.